Article

A quantitative assessment of sleep laboratory activity in the United States.

Division of Sleep Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine (Impact Factor: 2.83). 02/2005; 1(1):23-6.
Source: PubMed

ABSTRACT To determine the total number of active sleep laboratories in the United States and the number of polysomnograms conducted on a yearly basis in these laboratories.
All members of the AASM and all AASM accredited sleep laboratory directors received a questionnaire addressing their laboratory and its volume. In three states, multiple telephone calls to AASM members were used to correctly identify the absolute number of labs and their PSG volume in those states. Extrapolating from the number of labs studies identified per questionnaire relative to the correct number (per calls) in those states and, then applying this ratio to the entire US, the total number of labs and studies was determined.
Our data suggests that there are, in the year 2001, 1,292 sleep laboratories conducting 1,165,135 polysomnograms per year. This comes to 427 PSG's/year per 100,000 population in the United States.
These data suggest that there are a relatively large number of sleep laboratories in the US conducting a substantial number of PSG's. However, there was considerable variability in this volume between states that did not relate to known markers of healthcare utilization. These numbers have likely increased since 2001.

Download full-text

Full-text

Available from: Naoko Tachibana, May 15, 2015
0 Followers
 · 
114 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Obstructive sleep apnoea is a highly prevalent but under-diagnosed disorder. The gold standard for diagnosis of obstructive sleep apnoea is inpatient polysomnography. This is resource intensive and inconvenient for the patient, and the development of ambulatory diagnostic modalities has been identified as a key research priority. SleepMinder (BiancaMed, NovaUCD, Ireland) is a novel, non-contact, bedside sensor, which uses radio-waves to measure respiration and movement. Previous studies have shown it to be effective in measuring sleep and respiration. We sought to assess its utility in the diagnosis of obstructive sleep apnoea. SleepMinder and polysomnographic assessment of sleep-disordered breathing were performed simultaneously on consecutive subjects recruited prospectively from our sleep clinic. We assessed the diagnostic accuracy of SleepMinder in identifying obstructive sleep apnoea, and how SleepMinder assessment of the apnoea-hypopnoea index correlated with polysomnography. Seventy-four subjects were recruited. The apnoea-hypopnoea index as measured by SleepMinder correlated strongly with polysomnographic measurement (r = 0.90; P ≤ 0.0001). When a diagnostic threshold of moderate-severe (apnoea-hypopnoea index ≥15 events h(-1) ) obstructive sleep apnoea was used, SleepMinder displayed a sensitivity of 90%, a specificity of 92% and an accuracy of 91% in the diagnosis of sleep-disordered breathing. The area under the curve for the receiver operator characteristic was 0.97. SleepMinder correctly classified obstructive sleep apnoea severity in the majority of cases, with only one case different from equivalent polysomnography by more than one diagnostic class. We conclude that in an unselected clinical population undergoing investigation for suspected obstructive sleep apnoea, SleepMinder measurement of sleep-disordered breathing correlates significantly with polysomnography.
    Journal of Sleep Research 11/2012; DOI:10.1111/j.1365-2869.2012.01056.x · 2.95 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Obstructive sleep apnea (OSA), a highly prevalent breathing disorder in sleep, characterized by intermittent and recurrent pauses in respiration, has emerged as an independent risk factor for cardiovascular morbidity and mortality. Accumulated evidence implicates Leukocyte-endothelial cell activation and adhesion as critical components that induce inflammation and injury to the vasculature resulting in the development of cardiovascular complications. Similar cellular interactions were described in conditions of ischemia/reperfusion, and various components of the metabolic syndrome as hypercholesterolemia and hypertension. The hallmark of sleep apnea--the multiple cycles of hypoxia/reoxygenation--promote oxidative stress and inflammation. These facilitate increased interactions of blood cells with endothelial cells, resulting in endothelial cell injury and dysfunction. Such events can promote atherosclerosis and the development of cardiovascular morbidities in OSA. However, inter-individual differences in response to intermittent hypoxia and activation of anti-inflammatory cytokine profiles in T lymphocytes can serve as protective mechanisms.
    Archives of Physiology and Biochemistry 11/2008; 114(4):244-54. DOI:10.1080/13813450802306701
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Obstructive sleep apnea (OSA) is a serious, common, and underdiagnosed disorder that challenges health care resources. While polysomnography (PSG) represents the standard diagnostic test for OSA, portable devices provide an alternative diagnostic tool when issues of cost, time, geographic availability, or other constraints pose impediments to in-lab testing. This study compares the NovaSom QSG, a new sleep apnea home diagnostic system, to PSG both in the laboratory and in the home. Fifty-one consecutive adults referred to the sleep lab for suspicion of OSA underwent one night of in-lab, simultaneous recording of PSG and NovaSom QSG in addition to using the NovaSom QSG at home for three nights. Two separate comparisons were made using the apnea-hypopnea index (AHI): in-lab PSG to in-lab NovaSom QSG and in-lab PSG to home NovaSom QSG. Using a clinical cut-off of AHI=15, the sensitivity and specificity of the in-lab NovaSom QSG vs. PSG were 95% and 91%, respectively. For home NovaSom QSG vs. in-lab PSG, the sensitivity was 91% and specificity was 83%. The intra-class correlation coefficient for the agreement between three separate nights of NovaSom QSG home data was 0.88. In a patient population suspected of having OSA, the NovaSom QSG demonstrated acceptable sensitivity and specificity both in the lab and self-administered in the home, when compared to PSG.
    Sleep Medicine 06/2003; 4(3):213-8. DOI:10.1016/S1389-9457(02)00234-4 · 3.10 Impact Factor